

EULAR 2008

Thursday 12 June 2008

Oral session

| | Abstract No. | Abstract title | Author/ Co-Authors details | Time & Location |
|---|--------------|--|---|-----------------------------------|
| R | OP-0063 | EFFICACY AND SAFETY OF RITUXIMAB IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS | R. V. Denisova, E. I. Alexeyeva, T. M. Bzarova, H. Amital, S. I. Valiyeva, S. S. Akulova, K. B. Isayeva, A. M. Chomakhidze, A. O. Lisitsyn, E. Y. Gudkova | 10:15 - 11:45 Amphi Havane |
| T | OP-0064 | TOCILIZUMAB THERAPY SUPPRESSES THE EXPRESSION OF GENES RELATED TO THE MACROPHAGE ACTIVATION IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) | Toru Mima, Yasuo Adachi, Naoko Yoshio-Hoshino, Chieko Aoki, Satoru Ishikawa, Tomoyuki Imagawa, Masaaki Mori, Minako Tomiita, Naomi Iwata, Takuji Murata, Mari Miyoshi Miyoshi, Syuji Takei, Yukoh Aihara, Shumpei Yokota, Kenichi Matsubara, Norihiro Nishimoto | 10:15 - 11:45 Amphi Havane |
| T | OP-0112 | IL-6 PLUS SOLUBLE IL-6R INDUCES OSTEOCLAST FORMATION VIA UPREGULATION OF RANKL EXPRESSION ON FIBROBLAST-LIKE SYNOVIAL CELL | M. Hashizume, M. Mihara | 10:15 - 11:45 Room 353 |
| R | OP-0120 | EARLY B CELL REPOPULATION PREDICTS RELAPSE AFTER RITUXIMAB IN SLE | E. M. Vital, S. Dass, A. C. Rawstron, M. F. Martin, C. T. Pease, P. Emery | 13:30 - 15:00 Grand auditorium |

Thursday 12 June 2008

Roche Symposium

| | Abstract No. | Abstract title | Time & Location |
|---|--------------|-----------------------|---|
| T | | IL-6 Symposiums | 08:15 - 09:45 Palais des Congrès / Grand Amphi |
| R | | MabThera RA Symposium | 17 :30 – 19 :00 Palais des Congrès / Grand Amphi |

Thursday 12 June 2008
General Poster session

| | Abstract No. | Abstract title | Author/ Co-Authors details | Time & Location |
|----------|---------------------|---|---|----------------------------|
| R | THU0167 | CONTINUED INHIBITION OF STRUCTURAL DAMAGE IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH RITUXIMAB AT 2 YEARS: REFLEX STUDY | Stan Cohen, C Peterfy, David Hagerty, Tim Shaw, P Tak, Matt Cravets, Ed Keystone, Mark Genovese, Paul Emery | 11:45 - 13:30 |
| T | THU0168 | TOCILIZUMAB IMPROVES HEMOGLOBIN LEVELS AND FACIT-FATIGUE SCORES IN PATIENTS WITH RHEUMATOID ARTHRITIS | J. S. Smolen, M. Chester Wasko, C. R. Ramos-Remus, E. F. Mysler, B. Day, C. Wiese, R. Alten | 11:45 - 13:30 |
| T | THU0169 | ANALYSIS OF BASELINE DATA AND NEUTROPHIL COUNTS IN PATIENTS WITH SERIOUS INFECTIONS FROM TWO TOCILIZUMAB CLINICAL TRIALS | J. S. Smolen, R. Van Vollenhoven, A. Rubbert-Roth, H. Kellner, C. Ramos-Remus, B. Day, T. Woodworth, M. C. Genovese | 11:45 - 13:30 |
| T | THU0174 | EXPOSURE TO TOCILIZUMAB, AN INHIBITOR OF IL-6, IS ASSOCIATED WITH REDUCTIONS IN DISEASE ACTIVITY SCORE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A POPULATION PK/PD ANALYSIS | M. Levi, N. Frey, S. Grange, D. Schwab, T. Woodworth | 11:45 - 13:30 |
| T | THU0175 | POPULATION PK/PD ANALYSIS OF THE RELATIONSHIP BETWEEN TOCILIZUMAB EXPOSURE AND NEUTROPHIL COUNT IN PATIENTS WITH RHEUMATOID ARTHRITIS | Nicholas Frey, Valerie Cosson, Susan Grange, Dietmar Schwab, Thasia Woodworth | 11:45 - 13:30 |
| T | THU0176 | EFFECT OF TOCILIZUMAB EXPOSURE ON IL-6 AND IL-6 RECEPTOR LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS: GRAPHICAL ANALYSIS OF POOLED DATA FROM FOUR PHASE 3 CLINICAL TRIALS | Nicholas Frey, Micha Levi, Susan Grange, Dietmar Schwab, Thasia Woodworth | 11:45 - 13:30 |
| T | THU0177 | REDUCTION IN INFLAMMATORY BIOMARKERS WITH INCREASING EXPOSURE TO THE IL-6 INHIBITOR, TOCILIZUMAB, IN PATIENTS WITH RHEUMATOID ARTHRITIS: GRAPHICAL ANALYSIS OF POOLED DATA | Nicholas Frey, Thasia Woodworth, Susan Grange, Dietmar Schwab, Micha Levi | 11:45 - 13:30 |
| T | THU0178 | THE ANTI-IL6 RECEPTOR INHIBITOR TOCILIZUMAB (TCZ) COMBINED WITH METHOTREXATE (MTX) HAS BENEFICIAL EFFECTS ON BONE AND CARTILAGE METABOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA): RESULTS OF A PHASE III 24 WEEK RANDOMIZED PLACEBO CONTROLLED STUDY | Patrick Garner, Elisabeth Thompson, Thasia Woodworth, Emmanuel Mareau | 11:45 - 13:30 |

| | | | | |
|---|---------|---|---|---------------|
| T | THU0180 | THE TOWARD TRIAL: SIGNIFICANT AND RAPID REDUCTION IN DISEASE ACTIVITY WITH TOCILIZUMAB IN COMBINATION WITH SIX DIFFERENT DMARDS IN PATIENTS WITH RA HAVING INADEQUATELY RESPONDED TO DMARDS | Juan Gomez-Reino, Evgeniy Nasonov, James McKay, Eduardo Mysler, N da Silva, Emma Alecock, Thasia Woodworth, Mark Genovese | 11:45 - 13:30 |
| R | THU0181 | PROSPECTIVE FOLLOW-UP OF RITUXIMAB TREATMENT IN 804 PATIENTS WITH REFRACTORY RHEUMATOID ARTHRITIS (466 PATIENTS/YEAR) : TOLERANCE AND SAFETY DATA FROM THE FRENCH REGISTRY AIR (AUTOIMMUNITY AND RITUXIMAB) | Jacques-Eric Gottenberg, Xavier Mariette, Bernard Combe, Xavier Le Loët, Maxime Dougados, Philippe Ravaud, Thomas Bardin, Gabriel Baron, Jean Sibilia, Anne-Marie Taburet | 11:45 - 13:30 |
| R | THU0183 | SAFETY OF RITUXIMAB IN PATIENTS FAILING WITH AN INADEQUATE RESPONSE TO ONE ANTI-TNF AGENT. DATA FROM A JOINT CANADIAN AND SWEDISH COHORT | Boulous Haraoui, Maria Bokarewa, Vivian Bykerk, Ian Kallmeyer | 11:45 - 13:30 |
| T | THU0184 | TREATMENT WITH THE HUMANIZED ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY TOCILIZUMAB RESULTS IN RAPID IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS: RESULTS FROM A POOLED ANALYSIS OF CLINICAL TRIAL DATA FROM OPTION AND TOWARD | Ani John, Josef Smolen, Claire Davies, James McKay, Karel Pavelka, Andre Beaulieu | 11:45 - 13:30 |
| T | THU0185 | EFFICACY OF TOCILIZUMAB IN COMBINATION WITH DMARDS IS SUPERIOR TO DMARDS ALONE IN MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS BASED ON ACR CRITERIA: A POOLED ANALYSIS OF CLINICAL TRIAL DATA FROM OPTION AND TOWARD | Ani John, Cesar Ramos-Remus, Claire Davies, Andre Beaulieu, Mark Genovese, Josef Smolen | 11:45 - 13:30 |
| R | THU0188 | SDAI AND CDAI FOR PREDICTING OUTCOME OF A SECOND COURSE OF RITUXIMAB FOR PATIENTS WITH RHEUMATOID ARTHRITIS (RA) | Phillip Mease, Edward Keystone, Alan Kaell, Paul Emery, E St. Clair, Maxime Dougados, M Cravets, Tim Shaw, Akiko Chai, David Yocum | 11:45 - 13:30 |
| T | THU0199 | INCIDENCE OF INFECTIONS IN JAPANESE RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB (TCZ) IN CLINICAL STUDIES IN COMPARISON TO THOSE IN AN OBSERVATIONAL COHORT OF JAPANESE PATIENTS, IORRA | D. Hoshi, N. Nishimoto, E. Inoue, K. Shidara, A. Nakajima, M. Hara, T. Tomatsu, N. Kamatani, H. Yamanaka | 11:45 - 13:30 |

Friday 13 June 2008

Oral session

| | Abstract No. | Abstract title | Author/ Co-Authors details | Time & Location |
|----------|---------------------|--|--|------------------------------------|
| T | OP-0131 | TOCILIZUMAB MONOTHERAPY IS SUPERIOR TO METHOTREXATE MONOTHERAPY IN REDUCING DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE AMBITION STUDY | G. Jones, J. R. Gu, M. Lowenstein, A. Calvo, J. J. Gomez-Reino, D. Siri, M. Tomsic, R. Blackburn, T. Woodworth, A. Sebba | 10.15-11:45 grand auditorium |
| T | OP-0135 | RELATIONSHIP BETWEEN SERUM IL-6 LEVELS AFTER TOCILIZUMAB TREATMENT AND CLINICAL REMISSION IN ACTIVE RHEUMATOID ARTHRITIS (RA) PATIENTS | N. Nishimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, T. Mima, T. Suwabe, Y. Kawata, T. Kakehi | 10.15-11:45 grand auditorium |
| R | OP-0136 | RESIDUAL INFLAMMATION AFTER RITUXIMAB TREATMENT IS ASSOCIATED WITH SUSTAINED SYNOVIAL B-CELL INFILTRATION AND ENHANCED REPOPULATION OF CIRCULATING B-CELLS | Y. Teng, N. Levarht, R. E. M. Toes, T. W. J. Huizinga, J. M. van Laar | 10.15-11:45 grand auditorium |
| R | OP-0185 | RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH RITUXIMAB SHOWED NO MEAN EROSION PROGRESSION, BUT A SMALL TENDENCY TOWARDS REGRESSION, ON MAGNETIC RESONANCE IMAGING (MRI) AND CONVENTIONAL RADIOGRAPHY 1 YEAR AFTER TREATMENT | U. Møller Døhn, P. Bird, M. Østergaard, A. Boonen, J. S. Johansen, J. M. Møller, M. S. Hansen | 10.15-11:45 Amphi Havane |

Friday 13 June 2008

Poster session

| | Abstract No. | Abstract title | Author/ Co-Authors details | Time & Location |
|----------|---------------------|---|---|----------------------------|
| T | FRI0153 | THREE-YEAR EXTENSION OF THE SAMURAI STUDY CONFIRMS TOCILIZUMAB TO PREVENT JOINT DESTRUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS | N. Nishimoto, J. Hashimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, N. Murata, D. Van der Heijde | 11:45 - 13:30 |
| T | FRI0154 | SAFETY PROFILE OF TOCILIZUMAB IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS -INCIDENCES OF INFECTIONS IN JAPANESE LONG-TERM CLINICAL STUDIES | N. Nishimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, K. Ito, T. Kakehi | 11:45 - 13:30 |

| | | | | |
|---|---------|---|--|---------------|
| T | FRI0163 | SAFETY OF TOCILIZUMAB IN PATIENTS WITH RA WITH INADEQUATE RESPONSE TO DMARDS | J. Smolen, R. Bonfiglioli, A. Beaulieu, A. Alonso, J. Rovensky, E. Fishelva, B. Day, M. Genovese | 11:45 - 13:30 |
| T | FRI0164 | EFFICACY AND SAFETY OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS IN PATIENTS ABOVE AND BELOW 65 YEARS OF AGE WITH AN INADEQUATE RESPONSE TO DMARDS | J. Smolen, E. Martin-Mola, A. Rubbert-Roth, A. Beaulieu, C. Davies, A. John, M. Genovese | 11:45 - 13:30 |
| T | FRI0165 | IMMUNE RESPONSE TO INFLUENZA VACCINE IN PATIENTS DURING THE TREATMENT WITH TOCILIZUMAB – COMPARISON WITH CONVENTIONAL DMARDS AND TNF INHIBITORS | T. Tsuru, M. Suzaki, N. Yoshio, T. Mima, H. Nakashima, T. Amamoto, C. Aoki, A. Uchino, K. Terao, T. Takehi, N. Nishimoto | 11:45 - 13:30 |
| T | FRI0166 | DRUG-DISEASE INTERACTION STUDY OF TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS - IL-6 SIGNAL INHIBITION NORMALIZED CYTOCHROME P-450 ENZYMES EXPRESSION WHICH WAS REDUCED BY INFLAMMATION | K. Terao, T. Tsuru, M. Suzaki, Y. Ishida, T. Amamoto, H. Nakashima, T. Takehi, S. Higuchi, N. Nishimoto | 11:45 - 13:30 |
| R | FRI0168 | EXPERIENCE WITH RITUXIMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA): RESULTS FROM THE STURE REGISTRY | Ronald van Vollenhoven, Cheryl Cullinane Carli, Jenny Augustsson, Lars Klareskog | 11:45 - 13:30 |
| R | FRI0170 | THE GERMAN RITUXIMAB (RTX) TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS (RA) IN DAILY PRACTICE TRIAL: SECOND INTERIM ANALYSIS OF EFFECTIVENESS AND SAFETY AFTER 15 MONTHS | J. Wendler, H. Tony, A. Krause, G. Neeck, C. Richter, K. Haefner, H. Soerensen | 11:45 - 13:30 |
| T | FRI0172 | TOCILIZUMAB RAPIDLY AND SIGNIFICANTLY REDUCES DAS28 IN PATIENTS WITH RHEUMATOID ARTHRITIS INADEQUATELY RESPONDING TO DMARDS: POOLED ANALYSIS | J. Smolen, E. F. Mysler, A. Rubbert-Roth, J. Gomez-Reino, R. Alten, A. Law, T. Woodworth, M. Genovese | 11:45 - 13:30 |
| T | FRI0173 | LIVER TRANSAMINASES AND TOTAL BILIRUBIN LEVELS DURING TOCILIZUMAB TREATMENT IN PATIENTS WHO FAILED PRIOR DMARD TREATMENT | A. Beaulieu, B. Combe, A. Rubbert-Roth, T. Woodworth, A. Law, J. Smolen | 11:45 - 13:30 |
| T | FRI0174 | TOCILIZUMAB MONOTHERAPY IMPROVES QUALITY OF LIFE COMPARED WITH METHOTREXATE MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE AMBITION STUDY | A. I. Sebba, A. Calvo, X. Li, M. Lowenstein, V. Basijokiene, M. Saavedra-Salinas, T. Reitblat, R. Faraawi, A. Kivitz, R. Blackburn, T. Woodworth, G. Jones | 11:45 - 13:30 |
| R | FRI0193 | DESIGN AND BASELINE CHARACTERISTICS OF PATIENTS IN A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II/III STUDY (EXPLORER) TO EVALUATE THE EFFICACY AND SAFETY OF RITUXIMAB IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | J. T. Merrill, C. M. Neuwelt, D. J. Wallace, J. C. Shanahan, K. M. Latinis, J. C. Oates, T. O. Utset, C. Gordon, D. A. Isenberg, D. Zhang, P. G. Brunetta | 11:45 - 13:30 |

Saturday 14 June 2008

Oral session

| | Abstract No. | Abstract title | Author/ Co-Authors details | Time & Location |
|----------|---------------------|---|---|-----------------------------|
| T | OP-0245 | THE EFFICACY AND SAFETY OF TOCILIZUMAB IN THE TREATMENT OF EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS | M. C. Genovese, A. Rubbert-Roth, E. Nasonov, R. Alten, F. Schaefer, A. Law, J. S. Smolen | 08:45 - 10:15 Ternes |
| R | OP-0249 | WHICH SUBGROUP OF RHEUMATOID ARTHRITIS PATIENTS BENEFIT MOST FROM SWITCHING TO RITUXIMAB VERSUS ALTERNATIVE ANTI-TNF AGENTS AFTER PREVIOUS FAILURE TO ANTI-TNF AGENT? | Axel Finckh, Adrian Ciurea, Laure Brulhart, Burkhard Moeller, Ulrich Walker, Delphine Courvoisier, Diego Kyburz, Cem Gabay | 08:45 - 10:15 Amphi Bleu |
| T | OP-0251 | TOCILIZUMAB (TCZ) SIGNIFICANTLY IMPROVES DISEASE OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS WHOSE ANTI-TNF THERAPY FAILED: THE RADIATE STUDY | P. Emery, E. Keystone, H. Tony, A. Cantagrel, R. van Vollenhoven, A. Sanchez, E. Alecock, J. Lee, J. Kremer | 08:45 - 10:15 Amphi Bleu |
| O | OP-0250 | THE SAFETY AND EFFICACY OF OCRELIZUMAB; A HUMANIZED ANTI CD20 ANTIBODY ADMINISTERED AS A SINGLE INFUSION REGIMEN TO PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS | Carlos Chirinos-Rojas, Elena Ilivanova, Peter Boyd, Mark Dixon, Carmen Martin, Paul Tak, David Doyle, Juan Gomez Reino, Filip Van den Bosch, Janet Pope | 08:45 - 10:15 Amphi Bleu |

Exhibition hours:

Wednesday 11 June 2008 12:00 – 18:30
Thursday 12 June 2008 09:30 – 17:15
Friday 13 June 2008 09:30 – 17:15
Saturday 14 June 2008 09:30 – 15:00

Roche Stand: P42 & 44, Level 1, Exhibition Hall

R = rituximab (MabThera)

T = tocilizumab (Actemra)

O = ocrelizumab